Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 4/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386056 | 0.86 | FAAH (0.48) | KEAP1NFE2L2GPR119FAAHNAMPT | |
| SCHEMBL391117 | 0.84 | KEAP1 (0.51) | KEAP1NFE2L2GPR119FAAHNAMPT | |
| SCHEMBL390551 | 0.84 | GPR119 (0.50) | KEAP1NFE2L2GPR119NAMPTMEN1 | |
| SCHEMBL1073075 | 0.83 | POLB (0.40) | KEAP1NFE2L2MEN1ALDH1A1LMNA | |
| SCHEMBL389652 | 0.82 | FAAH (0.55) | KEAP1NFE2L2GPR119FAAH | |
| SCHEMBL27035706 | 0.82 | GPR119 (0.53) | KEAP1NFE2L2GPR119FAAH | |
| SCHEMBL389515 | 0.82 | GPR119 (0.48) | KEAP1NFE2L2GPR119FAAHNAMPT | |
| SCHEMBL387451 | 0.82 | GPR119 (0.48) | KEAP1NFE2L2GPR119FAAHUSP30 | |
| SCHEMBL389218 | 0.81 | GPR119 (0.54) | KEAP1NFE2L2GPR119FAAH | |
| SCHEMBL389329 | 0.80 | GPR119 (0.56) | KEAP1NFE2L2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7816364-B2 | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | GPR119, GLP1R, GPR4 | KEAP1 2576/4885NFE2L2 2723/4885GPR119 1/4885 |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | GPR119, GCGR, GPR65 | KEAP1 2420/4885NFE2L2 1605/4885GPR119 1/4885 |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | GPR119, GLP1R, GPR4 | KEAP1 2576/4885NFE2L2 2723/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.